A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
J. O'Shaughnessy
Consultant or Advisory Role - Sanofi
L. S. Schwartzberg
Consultant or Advisory Role - Sanofi
M. A. Danso
No relevant relationships to disclose
H. S. Rugo
No relevant relationships to disclose
K. Miller
No relevant relationships to disclose
D. A. Yardley
No relevant relationships to disclose
R. W. Carlson
No relevant relationships to disclose
R. S. Finn
No relevant relationships to disclose
E. Charpentier
No relevant relationships to disclose
M. Freese
No relevant relationships to disclose
S. Gupta
No relevant relationships to disclose
A. Blackwood-Chirchir
No relevant relationships to disclose
E. P. Winer
No relevant relationships to disclose